Anesiva Defines Regulatory Pathway For Adlea With FDA

Anesiva, Inc. (Nasdaq: ANSV) announced that it will conduct two Phase 3 clinical trials for the approval of Adlea(TM) — one of which has already been planned in total knee replacement surgeries — and the second trial in bunionectomy surgeries — for a broad product label of management of post-surgical pain associated with orthopedic surgeries. This decision is the result of continuing conversations with the Food and Drug Administration (FDA). [click link for full article]

More: continued here

Filed under: Pain / Anesthetics on October 11th, 2007